-
Placebo-Controlled
Evaluation of Study Drug in the Treatment of Alzheimer’s
Disease: Safety and Efficacy of a Controlled Release Formulation
-
NIMH/Clinical
Antipsychotic Trials of Intervention Effectiveness (Schizophrenia)
-
NIMH/Clinical
Antipsychotic Trials of Intervention Effectiveness (Alzheimer’s
Disease)
-
Study
Drug plus Study Drug Combination Therapy in Treatment-Resistant
Depression: A Dose Ranging Study
-
The
Assessment of Study Drug for the Treatment of Study Drug Associated
Weight Gain in Subjects with Schizophrenia, Schizophreniform
Disorder, Schizoaffective Disorder, and Bipolar I Disorder
-
A
Randomized Double-Blind Placebo-Controlled Trial to Evaluate
the Efficacy and Safety of Study Drug in Subjects with Mild
Cognitive Impairment (MCI) Clinically at Risk for Development
of Clinically Probable Alzheimer’s Disease
-
A
Controlled Trial of Study Drug versus Ziprasidone in the Treatment
of Schizophrenic and Schizoaffective Subjects with Comorbid
Depression
-
An
Open Label Extension Trial to Assess the Long Term Safety of
a Controlled Release Formulation of Study Drug in the Treatment
of Alzheimer’s Dementia
-
A
Randomized, Double-Blind, Parallel-Group, Placebo-Controlled
Study Evaluating the Efficacy and Safety of Study Drug (10 mg/day
and 20 mg/day) and Citalopram (20 mg/day) in Patients with Major
Depressive Disorder
-
The
Clinical Assessment of the Performance of the Study Procedure
in the Differential Diagnosis of Patients with Probable Alzheimer’s
Dementia from those Patients with Non-Alzheimer’s Dementing
Illnesses and Conditions
-
A
Multicenter, Double-blind, Randomized Comparison of the Efficacy
and Safety of Study Drug and Risperidone in the Treatment of
Patients with Schizophrenia
